Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study

BACKGROUND: Fingolimod was the first oral therapy approved for treating relapsing-remitting multiple sclerosis (RRMS) in 2010. This open-label study evaluated the safety and efficacy of fingolide(R), 0.5 mg in Iranian MS patients during one-year follow-up. METHODS: A multicenter, open-label, longitu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Caspian J Intern Med
Main Authors: Doosti, Rozita, Naser Moghadasi, Abdorreza, Azimi, Amir Reza, Karbalai Saleh, Shahrokh, Etemadifar, Masoud, Shaygannejad, Vahid, Ashtari, Fereshteh, Harirchian, Mohammad Hossein, Siroos, Seyed Bahaadin, Ayramloo, Hormoz, Majdinasab, Nastaran, Hojjati, Seyyed Mohammad Masood, Asghari, Nabiollah, Baghbanian, Seyed Mohammad, Cheraghmakani, Hamed, Abedini, Mahmoud, Sedighi, Behnaz, Mohseni Abbas abadi, Negar, Ghasemitabar, Maedeh, Talebianpour, Sara, Babayi Daylari, Tohid, Dana, Vahid, Ghaleh noie, Neda, Sahraian, Mohammad Ali
Formato: Artigo
Idioma:Inglês
Publicado em: Babol University of Medical Sciences 2021
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8223042/
https://ncbi.nlm.nih.gov/pubmed/34221275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22088/cjim.12.3.263
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados